TD Asset Management Inc Has $1.36 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

TD Asset Management Inc lowered its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 35.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,009 shares of the medical research company's stock after selling 4,978 shares during the period. TD Asset Management Inc's holdings in Charles River Laboratories International were worth $1,356,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Rothschild Investment LLC lifted its position in shares of Charles River Laboratories International by 480.0% during the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock valued at $26,000 after acquiring an additional 144 shares during the last quarter. HM Payson & Co. purchased a new stake in shares of Charles River Laboratories International during the first quarter valued at $31,000. Optiver Holding B.V. acquired a new position in shares of Charles River Laboratories International in the 4th quarter valued at $37,000. GeoWealth Management LLC boosted its position in shares of Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after purchasing an additional 190 shares during the period. Finally, Huntington National Bank increased its stake in Charles River Laboratories International by 120.6% in the 4th quarter. Huntington National Bank now owns 300 shares of the medical research company's stock worth $55,000 after purchasing an additional 164 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock traded down $0.15 during mid-day trading on Thursday, reaching $150.19. The company had a trading volume of 699,474 shares, compared to its average volume of 1,287,047. The company has a 50 day moving average of $155.03 and a 200-day moving average of $149.60. The firm has a market cap of $7.38 billion, a price-to-earnings ratio of -230.29, a PEG ratio of 5.67 and a beta of 1.48. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.78. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $230.02.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. During the same period last year, the firm earned $2.80 EPS. The firm's revenue for the quarter was up .6% compared to the same quarter last year. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president directly owned 19,513 shares of the company's stock, valued at $2,837,385.33. The trade was a 2.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

CRL has been the topic of several recent analyst reports. Robert W. Baird boosted their target price on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research note on Thursday, May 8th. Citigroup upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $150.00 to $200.00 in a research report on Wednesday, July 9th. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and dropped their target price for the company from $188.00 to $182.00 in a report on Friday, May 23rd. TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target for the company in a research report on Wednesday, May 14th. Finally, Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $175.31.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).